Edoxaban pharmacokinetics during in vitro continuous renal replacement therapy
For CRRT flow rates most employed in clinical practice, an edoxaban dose of 45 mg once daily is predicted to achieve target systemic exposure thresholds for venous thromboembolism treatment. The safety and efficacy of this proposed dosing warrants further investigation in clinical studies.
Authors
- Lauren Andrews (ORCID: https://orcid.org/0000-0003-3002-230X)
- Scott Benken (ORCID: https://orcid.org/0000-0002-8811-2458)
- Kaitlyn Dalton
- Eric Wenzler (ORCID: https://orcid.org/0000-0003-3914-8400)
Institutions
- University of Illinois Chicago (US)
- University of Colorado Health (US)
- St. David’s HealthCare (US)
Publication Details
- Journal
- BMC Nephrology
- Published
- 2024-10-10
- DOI
- https://doi.org/10.1186/s12882-024-03777-7
- Citations
- 1
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.40
Funders
- Daiichi Sankyo Europe